Low-dosage atypical antipsychotic drug composition
What is Al technical title?
Al technical title is built by PatSnap Al team. It summarizes the technical point description of the patent document.
An antipsychotic drug and atypical technology, applied in the field of medicine, can solve the problems of patients with residual negative symptoms, reduce patient compliance, shorten life expectancy, etc., achieve the effect of reducing medical costs, reducing cardiac side effects, and eliminating negative symptoms
Inactive Publication Date: 2018-12-07
FIRST HOSPITAL OF SHANXI MEDICAL UNIV
View PDF1 Cites 0 Cited by
Summary
Abstract
Description
Claims
Application Information
AI Technical Summary
This helps you quickly interpret patents by identifying the three key elements:
Problems solved by technology
Method used
Benefits of technology
Problems solved by technology
[0004] More than 50% of diagnosed SCZ patients have long-term intermittent psychotic symptoms, and most patients have residual negative symptoms, cognitive deficits, poor social function and even mental disability, and their life expectancy is shortened by 10 to 20 years
Dose increases may result in more serious side effects, which in turn may reduce patient compliance
Method used
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more
Image
Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
Click on the blue label to locate the original text in one second.
Reading with bidirectional positioning of images and text.
Smart Image
Examples
Experimental program
Comparison scheme
Effect test
Embodiment 1
[0048] According to the conventional capsule preparation method, 62.5g of ziprasidone, 125g of sertraline hydrochloride, 300g of cornstarch, 300g of hydroxypropyl cellulose, 120g of magnesium oxide, 60g of talcum powder, and 32.5g of micropowder silica gel were mixed to form granules, and The filling amount of each 200 mg is packed into capsules to make 5000 capsule preparations, each capsule preparation contains 12.5 mg of ziprasidone and 25 mg of sertraline hydrochloride.
Embodiment 2
[0050] Adopt conventional preparation method, ziprasidone 40g, sertraline hydrochloride 40g, cornstarch 80g, carboxymethyl starch sodium 100g, talcum powder 20g, magnesium stearate 10g, microcrystalline cellulose 10g are mixed to make powder, use The powder was compressed by a rotary tablet press to make 2000 tablets, each 150 mg, containing 20 mg of ziprasidone and 20 mg of sertraline hydrochloride.
Embodiment 3
[0052] Screen and collect 468 cases of schizophrenia patients meeting the inclusion criteria and exclusion criteria to evaluate the effect of the clinical trial of the pharmaceutical composition of the present invention, and divide the subjects into an experimental group and a control group at random, with 234 cases in each group.
[0053] Inclusion criteria: 1) Meet the diagnostic criteria for schizophrenia in DSM-IV; 2) Educational years ≥ 9 years, right-handed, Han nationality, 3) Age 18-60 years old; 4) Have not received any medical treatment 2 weeks before enrollment 5) half a year ≤ total disease duration ≤ 30 years; 6) PANSS score ≥ 60 points; 7) signed the informed consent.
[0054]Exclusion criteria: 1) Those who are known to be allergic to the drugs used, those who have recent pregnancy plans or breastfeeding; 2) Recent acute myocardial infarction, decompensated heart failure, and a history of prolonged QT interval (including congenital long QT interval 3) Those who ...
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
PUM
Login to view more
Abstract
The invention relates to a low-dosage atypical antipsychotic drug composition. The low-dosage atypical antipsychotic drug composition comprises active components, i.e., ziprasidone and sertraline hydrochloride with the weight ratio being 0.5:1-2:1, and the active components with the dosage being 120-150mg/d, in which the dosage of the ziprasidone is 40-100mg/d, is applied to treatment of SCZ (Schizophrenia). In the low-dosage atypical antipsychotic drug composition, low-dosage ziprasidone and sertraline hydrochloride have good synergistic effect, and compared with use of the ziprasidone with medium-high dosage to treat the SCZ, not only is the effect for eliminating positive symptoms equivalent, but also the effect for eliminating negative symptoms and affective symptoms is more obvious and the social function of SCZ patients is improved; simultaneously, the QTc interval prolongation of electrocardiogram due to the ziprasidone with medium-high dosage is greatly reduced, and the occurrence probability of other adverse cardiovascular events such as TdP (Torsades De Pointes) risk and sudden death and the like is reduced.
Description
technical field [0001] The invention belongs to the technical field of medicine and relates to a pharmaceutical composition, in particular to an antipsychotic pharmaceutical composition, which can effectively treat schizophrenia with a low dose of the pharmaceutical composition of the invention. Background technique [0002] Schizophrenia (SCZ) is a chronic severe mental illness with high recurrence rate, high disability rate, high mortality rate and high disease burden, which is extremely harmful to human health, and its etiology is unknown so far. 1%. [0003] The main symptoms of SCZ include positive symptoms, negative symptoms, affective symptoms and cognitive symptoms. Positive symptoms mainly include hallucinations, delusions, disorganized speech and behavior, nervous or agitated behavior; negative symptoms mainly include emotional bluntness or incoordination, reduced social interaction, withdrawn and withdrawn, lack of speech and interest, decreased willpower, lazy l...
Claims
the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more
Application Information
Patent Timeline
Application Date:The date an application was filed.
Publication Date:The date a patent or application was officially published.
First Publication Date:The earliest publication date of a patent with the same application number.
Issue Date:Publication date of the patent grant document.
PCT Entry Date:The Entry date of PCT National Phase.
Estimated Expiry Date:The statutory expiry date of a patent right according to the Patent Law, and it is the longest term of protection that the patent right can achieve without the termination of the patent right due to other reasons(Term extension factor has been taken into account ).
Invalid Date:Actual expiry date is based on effective date or publication date of legal transaction data of invalid patent.
Login to view more 
Login to view more